Treatment with the GLP-1RA dulaglutide for a median of 5.4 years resulted in a reduction of cognitive impairment compared to placebo in T2DM patients ≥50 years, in an exploratory analysis of REWIND.
A diagnostic model based on symptoms partly uncovered unrecognized AF, HF and CAD in participants from the Lifelines cohort study. This resulted in the development of an 11-item questionnaire for proactive screening.
Members of the Diabetes and Cardiovascular Disease EASD Study Group have published a perspective on issues of CV risk management in diabetes patients during the COVID-19 pandemic.
This study showed that the most frequent first manifestations of CV- and renal disease in T2D patients were HF and CKD, which were both associated with increased all-cause and CVD mortality risk.
A consensus document by a group of representatives from primary and secondary care has been published on the management of diabetes for patients at risk or with confirmed COVID-19.
Treatment with liraglutide plus lifestyle therapy led to a greater reduction in BMI standard-deviation score than placebo plus lifestyle therapy in adolescents with obesity.
ACC 2020 COMPASS Diabetes compared treatment of low-dose rivaroxaban plus aspirin with aspirin alone in stable CAD and/or PAD patients with or without diabetes.
An analysis of the EUROASPIRE V survey showed that dysglycemia in CAD patients was unrecognized in a large portion of patients, while two thirds of CAD patients have T2DM or IGT.
This study evaluated a community-based screening approach in 8 barbershops in Brooklyn, New York and found a prevalence of undiagnosed diabetes in 9.0% of the black male participants.
The European Society of Cardiology (ESC) Atlas working group has published a report on CVD statistics in 2019 across 56 member countries of the ESC.
DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.
Although diabetes care is highly organized in the Netherlands, CV morbidity and mortality rates in T2DM patients have not come down from 2008 to 2016 and life years lost remains considerably high.